Trastuzumab

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17835 publications

Title Not Found

Title Not Found

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
Published: September 08, 2026

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology
Published: September 03, 2026

Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.

Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.

Journal: The American journal of case reports
Published: September 02, 2026

Correction to "Real-Time Monitoring of Trastuzumab Monoclonal Antibodies Using Electrochemical Aptamer-Based Sensors".

Correction to "Real-Time Monitoring of Trastuzumab Monoclonal Antibodies Using Electrochemical Aptamer-Based Sensors".

Journal: ACS sensors
Published: September 02, 2026

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

Journal: Future oncology (London, England)
Published: September 02, 2026

Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.

Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.

Journal: European review for medical and pharmacological sciences
Published: September 01, 2026

HER2 ultralow in metastatic breast cancer: Diagnostic boundaries in the era of antibody-drug conjugates.

HER2 ultralow in metastatic breast cancer: Diagnostic boundaries in the era of antibody-drug conjugates.

Journal: The Malaysian journal of pathology
Published: August 31, 2026

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.

Journal: JAMA oncology
Published: August 27, 2026

Osimertinib-Associated Cardiotoxicity in EGFR-Mutant Non-Small Cell Lung Cancer: Mechanisms, Phenotypes, and Surveillance.

Osimertinib-Associated Cardiotoxicity in EGFR-Mutant Non-Small Cell Lung Cancer: Mechanisms, Phenotypes, and Surveillance.

Journal: Cardiology in review
Published: August 24, 2026

Resolution of Osteoporosis in a Breast Cancer Survivor Following Supervised Osteogenic Loading and High-Adherence Lifestyle Modification: A Case Report.

Resolution of Osteoporosis in a Breast Cancer Survivor Following Supervised Osteogenic Loading and High-Adherence Lifestyle Modification: A Case Report.

Journal: Cureus
Published: August 24, 2026

HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy.

HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy.

Journal: BMJ case reports
Published: August 24, 2026

Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.

Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: August 20, 2026
Showing 1-12 of 17,835

Last Updated: 09/26/2026